Background
• Glaucoma drainage implants (GDI) have been used with increasing frequency in the management of glaucoma refractive to trabeculectomy, even in the era of antimetabolite use. Medicare data reveals a marked increase in the use of GDIs, from just over 2,000 in 1994 to almost 12,000 in 2012.
• In addition, surveys of the membership of the American Glaucoma Society performed in 1996, 2002, and 2008 show a significant increase in the use of GDIs in patients who had undergone prior surgery This shift in practice pattern has been validated by the results of the Tube Versus Trabeculetomy (TVT) Study, which found that patients with prior trabeculectomy and/or prior cataract surgery had a higher success rate with GDI surgery compared with trabeculectomy with mitomycin-C.
Purpose:
• Methods:
• Patients aged 18-85 years with refractory glaucoma, and IOPs greater than or equal to 18 mmHg in whom GDI surgery was planned were enrolled in the study.
• Patients with primary glaucomas with a previous failed trabeculectomy or other intraocular surgery were included.
• Also, patients without previous intraocular surgery were eligible if they had secondary glaucomas known to have a higher risk of trabeculectomy failure such as neovascular glaucoma (NVG), uveitic glaucoma, or glaucoma associated with iridocorneal endothelialization syndrome. 
Discussion
• The lower IOPs in the BGI group were achieved with fewer glaucoma medications compared with the AGV group at most time intervals.
• There are two reasons that may be offered to explain the superior IOP control observed with the BGI relative to the AGV. First, studies have shown that glaucoma drainage devices with larger end plates result in lower IOPs.
Discussion ( cont)
• The second possible explanation for lower long term IOPs with the BGI relates to exposure of the filtering bleb to postoperative inflammatory material. In the valved AGV, there is immediate flow of aqueous to the bleb, exposing it to inflammatory cells and protein resulting from the surgery, which may produce more vigorous scarring of the fibrous capsule surrounding the end plate. In the non-valved BGI, complete occlusion of the tube for the first four to six weeks is critical to prevent early hypotony and hypotony-related complications such as flat anterior chambers, choroidal effusions, and suprachoroidal hemorrhages.
Discussion (cont)
• By occluding the BGI for a period of several weeks, the bleb is exposed to much less inflammatory material. Whatever the explanation, the larger, non-valved BGI tends to produce better long-term IOP control, which may make it the preferred implant in patients in whom one is trying to achieve the lowest possible IOP postoperatively Discussion ( cont)
• There are several limitations to the ABC Study. Neither the patient nor the surgeon was masked to the implant used.
• The study only evaluated the AGV and BGI, and the results cannot be extrapolated to other GDIs or different models of the AVG or BGI.
• Patients were excluded if other ocular procedures were required in conjunction with glaucoma surgery, so the study does not provide information about the preferred implant when concurrent ocular surgery is needed.
Conclusion
• The NVG group has the highest failure rates of the four strata in our study.
• NVG accounts for 17 (89%) of the 19 losses of light perception in the study.
• BGI implantation produced greater IOP reduction and a lower rate of glaucoma reoperation than AGI implantation during 5 years of follow-up.
• Similar rates of surgical success were observed with both implants at 5 years.
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